Form 4: Repare Therapeutics Director Acquires Stock Options

Director Steven H. Stein acquired stock options for 54,000 common shares of Repare Therapeutics Inc. on June 17, 2024.

Summary

• Steven H. Stein, a director of Repare Therapeutics Inc., acquired stock options on June 17, 2024.
• The options grant the right to buy 54,000 common shares at an exercise price of $3.80.
• The options vest over a three-year period, with one-third vesting on June 17, 2025, and the remainder vesting monthly thereafter, contingent upon continued service.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The granting of options is generally viewed as a positive, but it's a standard practice.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the options is contingent upon the reporting person's continued service with the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management with those of shareholders.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.

Key Dates